Cargando…

Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients

Immunocompromised subjects are at risk of severe viral infections which may require intensive care unit (ICU) admission. Data on the outcome of influenza pneumonia in critically-ill immunocompromised subjects are limited. We conducted a single-center observational study. All subjects admitted to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Raymond, Matthieu, Martin, Maëlle, Lamouche-Wilquin, Pauline, Blonz, Gauthier, Decamps, Paul, Agbakou, Maïté, Desmedt, Luc, Reignier, Jean, Lascarrou, Jean-Baptiste, Canet, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750560/
https://www.ncbi.nlm.nih.gov/pubmed/36626482
http://dx.doi.org/10.1097/MD.0000000000032245
_version_ 1784850282597842944
author Raymond, Matthieu
Martin, Maëlle
Lamouche-Wilquin, Pauline
Blonz, Gauthier
Decamps, Paul
Agbakou, Maïté
Desmedt, Luc
Reignier, Jean
Lascarrou, Jean-Baptiste
Canet, Emmanuel
author_facet Raymond, Matthieu
Martin, Maëlle
Lamouche-Wilquin, Pauline
Blonz, Gauthier
Decamps, Paul
Agbakou, Maïté
Desmedt, Luc
Reignier, Jean
Lascarrou, Jean-Baptiste
Canet, Emmanuel
author_sort Raymond, Matthieu
collection PubMed
description Immunocompromised subjects are at risk of severe viral infections which may require intensive care unit (ICU) admission. Data on the outcome of influenza pneumonia in critically-ill immunocompromised subjects are limited. We conducted a single-center observational study. All subjects admitted to the ICU for influenza pneumonia between 2016 and 2020 were included. The main objective was to compare the clinical features and outcome of critically-ill subjects with flu according to their immune status. 137 subjects (age 60 years-old, 58.4% male) were included, of whom 58 (42.34%) were intubated during the ICU stay. Forty-three (31.4%) subjects were immunocompromised. Immunocompromised subjects had a higher Charlson comorbidity index. In contrast, severity scores and hypoxemia at ICU admission, and ventilatory support during ICU stay were similar between the 2 groups. There was no difference in the rate of co-infections and ventilator-associated pneumonia between the 2 groups. Among intubated subjects, 10 (23.26%) immunocompromised subjects developed severe acute respiratory distress syndrome compared to 13 (13.83%) non-immunocompromised (P = .218). ICU mortality was 13.97%, with mortality being 3-times higher in immunocompromised subjects (25.58% vs 8.6%, P = .015). On multivariable analysis, immunocompromised status, higher age and lower arterial oxygen partial pressure/fraction of inspired oxygen were associated with an increased ICU mortality. Immunocompromised subjects with severe influenza pneumonia were more likely to develop severe acute respiratory distress syndrome and had a 3-fold increase in ICU mortality compared to non-immunocompromised subjects. Such difference was not explained by an increased rate of co-infections or nosocomial pneumonia, suggesting that influenza virus was by itself responsible of a more severe form of pulmonary disease in immunocompromised subjects.
format Online
Article
Text
id pubmed-9750560
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97505602022-12-28 Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients Raymond, Matthieu Martin, Maëlle Lamouche-Wilquin, Pauline Blonz, Gauthier Decamps, Paul Agbakou, Maïté Desmedt, Luc Reignier, Jean Lascarrou, Jean-Baptiste Canet, Emmanuel Medicine (Baltimore) 3900 Immunocompromised subjects are at risk of severe viral infections which may require intensive care unit (ICU) admission. Data on the outcome of influenza pneumonia in critically-ill immunocompromised subjects are limited. We conducted a single-center observational study. All subjects admitted to the ICU for influenza pneumonia between 2016 and 2020 were included. The main objective was to compare the clinical features and outcome of critically-ill subjects with flu according to their immune status. 137 subjects (age 60 years-old, 58.4% male) were included, of whom 58 (42.34%) were intubated during the ICU stay. Forty-three (31.4%) subjects were immunocompromised. Immunocompromised subjects had a higher Charlson comorbidity index. In contrast, severity scores and hypoxemia at ICU admission, and ventilatory support during ICU stay were similar between the 2 groups. There was no difference in the rate of co-infections and ventilator-associated pneumonia between the 2 groups. Among intubated subjects, 10 (23.26%) immunocompromised subjects developed severe acute respiratory distress syndrome compared to 13 (13.83%) non-immunocompromised (P = .218). ICU mortality was 13.97%, with mortality being 3-times higher in immunocompromised subjects (25.58% vs 8.6%, P = .015). On multivariable analysis, immunocompromised status, higher age and lower arterial oxygen partial pressure/fraction of inspired oxygen were associated with an increased ICU mortality. Immunocompromised subjects with severe influenza pneumonia were more likely to develop severe acute respiratory distress syndrome and had a 3-fold increase in ICU mortality compared to non-immunocompromised subjects. Such difference was not explained by an increased rate of co-infections or nosocomial pneumonia, suggesting that influenza virus was by itself responsible of a more severe form of pulmonary disease in immunocompromised subjects. Lippincott Williams & Wilkins 2022-12-09 /pmc/articles/PMC9750560/ /pubmed/36626482 http://dx.doi.org/10.1097/MD.0000000000032245 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 3900
Raymond, Matthieu
Martin, Maëlle
Lamouche-Wilquin, Pauline
Blonz, Gauthier
Decamps, Paul
Agbakou, Maïté
Desmedt, Luc
Reignier, Jean
Lascarrou, Jean-Baptiste
Canet, Emmanuel
Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
title Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
title_full Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
title_fullStr Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
title_full_unstemmed Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
title_short Clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
title_sort clinical features and outcome of influenza pneumonia in critically-ill immunocompromised patients
topic 3900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750560/
https://www.ncbi.nlm.nih.gov/pubmed/36626482
http://dx.doi.org/10.1097/MD.0000000000032245
work_keys_str_mv AT raymondmatthieu clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients
AT martinmaelle clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients
AT lamouchewilquinpauline clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients
AT blonzgauthier clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients
AT decampspaul clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients
AT agbakoumaite clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients
AT desmedtluc clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients
AT reignierjean clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients
AT lascarroujeanbaptiste clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients
AT canetemmanuel clinicalfeaturesandoutcomeofinfluenzapneumoniaincriticallyillimmunocompromisedpatients